دورية أكاديمية
Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.
| العنوان: | Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. |
|---|---|
| المؤلفون: | Kocak E; Division of Cancer Immunology, Department of Pathology, The Ohio State University Medical Center, Columbus, Ohio, USA., Lute K, Chang X, May KF Jr, Exten KR, Zhang H, Abdessalam SF, Lehman AM, Jarjoura D, Zheng P, Liu Y |
| المصدر: | Cancer research [Cancer Res] 2006 Jul 15; Vol. 66 (14), pp. 7276-84. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Print ISSN: 0008-5472 (Print) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Baltimore, Md. : American Association for Cancer Research Original Publication: Chicago [etc.] |
| مواضيع طبية MeSH: | Antibodies, Monoclonal/*pharmacology , Antigens, CD/*immunology , Antigens, Differentiation/*immunology , Antineoplastic Combined Chemotherapy Protocols/*pharmacology , Colonic Neoplasms/*therapy , Receptors, Nerve Growth Factor/*immunology , Receptors, Tumor Necrosis Factor/*immunology, Animals ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/immunology ; Antineoplastic Combined Chemotherapy Protocols/immunology ; Autoimmunity/immunology ; CD8-Positive T-Lymphocytes/immunology ; CTLA-4 Antigen ; Colonic Neoplasms/immunology ; Female ; Humans ; Immunization, Passive/methods ; Mice ; Mice, Inbred C57BL ; T-Lymphocytes, Regulatory/immunology ; Tumor Necrosis Factor Receptor Superfamily, Member 9 |
| مستخلص: | The majority of cancer antigens identified thus far have limited expression in normal tissues. It has been suggested that autoimmune disease is a necessary price for cancer immunity. This notion is supported by a recent clinical trial involving an anti-CTL antigen-4 (CTLA-4) antibody that showed significant clinical responses but severe autoimmune diseases in melanoma patients. To selectively modulate cancer immunity and autoimmunity, we used anti-CTLA-4 and anti-4-1BB antibodies to treat mice with a preexisting cancer, MC38. The combination of the two antibodies led to CD8 T-cell-mediated rejection of large established MC38 tumors and long-lasting immunity to the same tumor cells, although the same regimen was not effective for B16 melanoma. More importantly, whereas individual antibodies induced inflammation and autoimmune manifestations, combination therapy increased cancer immunity while reducing autoimmunity. The reduction of autoimmune effects correlates with an increased function of regulatory T cells. Our results suggest a novel approach to simultaneously enhance cancer immunity and reduce autoimmunity. |
| معلومات مُعتمدة: | P01CA95426 United States CA NCI NIH HHS; R01CA58033 United States CA NCI NIH HHS; R01CA69091 United States CA NCI NIH HHS; R41CA93107 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Antigens, CD) 0 (Antigens, Differentiation) 0 (CTLA-4 Antigen) 0 (CTLA4 protein, human) 0 (Ctla4 protein, mouse) 0 (Receptors, Nerve Growth Factor) 0 (Receptors, Tumor Necrosis Factor) 0 (TNFRSF9 protein, human) 0 (Tnfrsf9 protein, mouse) 0 (Tumor Necrosis Factor Receptor Superfamily, Member 9) |
| تواريخ الأحداث: | Date Created: 20060720 Date Completed: 20060919 Latest Revision: 20220310 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1158/0008-5472.CAN-05-2128 |
| PMID: | 16849577 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0008-5472 |
|---|---|
| DOI: | 10.1158/0008-5472.CAN-05-2128 |